1.
Dockendorff C, Faloon PW, Germain A, et al. Discovery of bisamide-heterocycles as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorg Med Chem Lett. 2015;25(12):2594-8. doi:10.1016/j.bmcl.2015.03.074.
1.
Rodriguez-Broadbent H, Law PJ, Sud A, et al. Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer. Int J Cancer. 2017;140(12):2701-2708. doi:10.1002/ijc.30709.
1.
Joshi PK, Pirastu N, Kentistou KA, et al. Genome-wide meta-analysis associates HLA-DQA1/DRB1 and LPA and lifestyle factors with human longevity. Nat Commun. 2017;8(1):910. doi:10.1038/s41467-017-00934-5.
1.
Nieland TJF, Shaw JT, Jaipuri FA, et al. Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry. 2008;47(1):460-72. doi:10.1021/bi701277x.
1.
Nieland TJF, Shaw JT, Jaipuri FA, et al. Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI. J Lipid Res. 2007;48(8):1832-45. doi:10.1194/jlr.M700209-JLR200.
1.
Yu M, Romer KA, Nieland TJF, et al. Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity. Proc Natl Acad Sci U S A. 2011;108(30):12243-8. doi:10.1073/pnas.1109078108.
1.
Genovese G, Friedman DJ, Pollak MR. APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol. 2013;9(4):240-4. doi:10.1038/nrneph.2013.34.
1.
Williams WW, Pollak MR. Health disparities in kidney disease--emerging data from the human genome. N Engl J Med. 2013;369(23):2260-1. doi:10.1056/NEJMe1312797.
1.
Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 2015;87(2):332-42. doi:10.1038/ki.2014.270.
1.
Ruchi R, Genovese G, Lee J, et al. Copy Number Variation at the APOL1 Locus. PLoS One. 2015;10(5):e0125410. doi:10.1371/journal.pone.0125410.